Amazon Prime could face investigation over delivery complaints
Industry lukewarm on scope and implementation of auto-enrolment review proposals
United States tech giant Oracle is buying Australia's Aconex for $1.6 billion
European Regulators Open Investigation Into Ikea's Taxes
Toyota to introduce its BEVs in India through 2020s
Analysts Review: Repros Therapeutics (RPRX)
12 October 2017, 05:08 | Kelvin Horton
Perhaps, that suggests something about why 17.60% of the outstanding share supply is held by institutional investors. Employing the use of the moving average for technical equity analysis is still highly popular among traders and investors. Considering that the stock daily volume of 16.41 million shares, this represents a pretty noteworthy trading in volume size. Breaking down insider in the United States, the Securities and Exchange Commission makes rules concerning insider trading. It is illegal when the material information is still non-public-trading while having special information is deceitful to other traders who do not have access to such information. It is measuring a stock's valuation (Price to Earning) against its projected 3-5 year growth rate. "Separately, Director Masterson Nola E Sell 3305 shares of the company at a price of $1.95 on 2016-11-21". Net profit margin of the company was recorded at 0 percent, operating profit margin was 0 percent, while gross profit margin stands at 0 percent. The empirical findings suggest that institutional trading as measured by institutional ownership flows prove to be a good gauge of stock returns. The company is given one point for every criteria that is met and no points if not met.
Annual EPS growth Past 5 years is 7.7 percent. The stock's short float is around of 2.23% and short ratio is 1.02.
RPRXs average Altman Z-Score: -84.90 in the past 7 years. Values of %D line that are above 80 indicate that the security is overbought; prices could well fall in the near future. For RPRX, the company now has $4.68 Million of cash on the books. FCF is an important factor as it enables a company to pursue opportunities that boost shareholder value.
Repros Therapeutics Inc. (NASDAQ:RPRX) has accumulated 53.27% over the course of one week. Book value refers to the total amount a firm would be worth if it liquidated its assets and paid back all its liabilities.
Repros Therapeutics Inc. (RPRX) shows its Return on Assets (ROA) value of -212.1 percent, while the Return on Equity (ROE) value is -412.4 percent and Return on Investment (ROI) value stands at 0 percent.
Another technical indicator that might serve as a powerful resource for measuring trend strength is the Average Directional Index or ADX.
Repros Therapeutics, Inc., launched on August 20, 1987, is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.
Repros Therapeutics Inc. (RPRX) has an Analysts' Mean Recommendation of 2.
After a recent technical review, shares of Repros Therapeutics (RPRX) have a 200-day moving average of 0.78. (RPRX) for the current quarter. RPRX reported a change of 131.48% over the last week and performed 149.58% over the last month while its year to date (YTD) performance revealed an activity trend of -43.18%.
The highest price RPRX stock touched in the last 12 month was $2.16 and the lowest price it hit in the same period was $0.26.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 3.18, and a price to sales ratio of 0.84. The true range indicator is the greatest of the following: current high less the current low, the absolute value of the current high less the previous close and the absolute value of the current low less the previous close.
Sensex, Nifty zoom ahead of results by TCS, Reliance Industries
Notably, the shares of TCS gained as the Indian IT bellwether is scheduled to announce its much awaited quarterly earnings today. Coal India , Hindustan Petroleum, and Kotak Mahindra bank lost more than 0.6% each in the opening trade on Thursday morning.